Evidence map›Paper›PMID 33171476›Full record

ArticleOphthalmic research2021

The Minimal Clinically Important Difference in Glaucoma Medication Adherence: Interviews of Glaucoma Experts.

Ajay Kolli, Shelby Daniel-Wayman, Paula Anne Newman-Casey

Abstract readNews
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmic research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. The Effects of Topical Timolol and Latanoprost on Calculated Ocular Perfusion Pressure in Nonglaucomatous Volunteers.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2021
    Trial
  6. Improving Adherence to Psychotherapy and Clinical Outcome in Patients With Late-Life Depression Through Gamified mHealth Technology.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ajay KolliUniversity of Michigan Medical School, Ann Arbor, Michigan, USA.
Shelby Daniel-WaymanDepartment of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan, USA.
Paula Anne Newman-CaseyDepartment of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan, USA, panewman@med.umich.edu.

Funding

Support, Educate, Empower: The SEE Personalized Glaucoma Coaching Trial: Diversity SupplementR01EY031337 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NEWMAN-CASEY, PAULA ANNE · 2020 to 2024
$3.9M
Improving glaucoma self-management with technology-supported counselorsK23EY025320 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NEWMAN-CASEY, PAULA ANNE · 2016 to 2019
$920k
NEI NIH HHS K23 EY025320NEI NIH HHS R01 EY031337
6 · The paper itself

Abstract

Poor adherence to glaucoma medications is associated with progressive vision loss. While many interventions have sought to increase glaucoma medication adherence, the amount by which adherence must increase to have a clinically significant effect remains unknown. To generate a hypothesized minimal clinically important difference (MCID) for glaucoma medication adherence, we conducted interviews with glaucoma experts. Semi-structured interviews were conducted with members of the American Glaucoma Society. MCID was defined in 2 ways: (1) the incremental increase in the average percentage of eye drops a patient takes at roughly the correct time and (2) the incremental increase in the proportion of a patient population who attain good adherence. Good adherence was defined as taking more than 80% of drops at approximately the prescribed dose time. Expert opinions on the MCID for glaucoma medication adherence and open-ended responses were recorded through field notes. Twenty-five experts were interviewed. They estimated the MCID for average individual adherence levels as 17.7% (95% CI: 14.6, 20.8). Experts estimated the MCID for the proportion of patients in a practice who attain good adherence (defined as >80% of eye drops taken as prescribed) as 18.5% (95% CI: 15.6, 21.5). The most common identified themes were that the MCID should take into account the cost of the intervention and the burden to the ophthalmologist and to the practice, where experts thought that more costly interventions or those that required more physician time should have larger MCIDs. Based on expert opinion, we hypothesized that the MCID for glaucoma medication adherence is between 15 and 20%. However, the MCID for a given intervention must take into account several factors, including intervention cost and physician burden. This hypothesis may facilitate the design and implementation of future studies to objectively determine an MCID for glaucoma medication adherence.

Indexed as

GlaucomaMinimal Clinically Important DifferenceHumansMedication AdherenceOphthalmic SolutionsOphthalmic SolutionsAdherenceGlaucomaMinimal clinically important difference

Identifiers

PMID33171476
PMCPMC9088219

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.